

1 **In-kind nutritional supplementation for household contacts of persons with tuberculosis would be**
2 **cost-effective for reducing tuberculosis incidence and mortality in India: a modeling study**

3
4
5 Pranay Sinha^{1,2}, Madolyn Dauphinais², Madeline E. Carwile², C. Robert Horsburgh, Jr.^{1,2,3} Nicolas A.
6 Menzies^{4,5}

7
8 1. Section of Infectious Diseases, Department of Medicine, Boston University Chobanian &
9 Avedisian School of Medicine, MA, USA

10 2. Boston Medical Center, Boston, MA, USA

11 3. Department of Epidemiology, Boston University School of Public Health, MA, USA

12 4. Center for Health Decision Sciences, Harvard TH Chan School of Public Health, Boston, MS,
13 USA

14 5. Department of Global Health and Population, Harvard TH Chan School of Public Health,
15 Boston, MA, USA

16
17 * Corresponding author

18 Abstract word count:249/250 word | Body word count: 3369/3500 words | References: 30/30

19
20 **Keywords:** Nutritional supplementation, tuberculosis, undernutrition, India, Health Economics

21 **Running title:** Nutritional supplementation for TB prevention

22 **Corresponding author:** Pranay Sinha, 801 Massachusetts Ave, Crosstown Building, Suite 2021A, Boston,
23 MA, USA 02119; email: psinha@bu.edu; phone: 516-633-9920

24
25 **Summary:** Undernutrition is the leading cause of tuberculosis in India. Using a Markov state-transition
26 model, we found that food baskets for household contacts of persons with tuberculosis would be cost-
27 effective in reducing tuberculosis incidence and mortality in India.

28
29 **Research in context**

30 *Evidence before this study:* Undernutrition is the leading risk factor for TB worldwide. Recently, the
31 RATIONS study demonstrated a roughly 40% reduction in incident TB among household contacts who
32 received in-kind macronutrient and micronutrient supplementation.

33
34 *Added value of this study:* Although the RATIONS study demonstrated a dramatic reduction in incident
35 TB, it is unclear if nutritional interventions to prevent TB are cost-effective. Previously, only one cost-
36 effectiveness analysis of nutritional interventions for household contacts has been published. Due to lack
37 of published data, that study had to make assumptions regarding the impact of nutritional interventions on
38 TB incidence and mortality. In this study, we conducted an economic evaluation of a RATIONS-style
39 intervention to reduce incident TB and mortality in India using observed data.

40
41 *Implications of all the available evidence:* In-kind nutritional supplementation for household contacts of
42 individuals with TB disease would be cost-effective in reducing incident TB and TB mortality,
43 particularly if TB programs leverage economies of scale to bring down the cost of the nutritional
44 intervention.

47 **ABSTRACT**

48 **Background:** Undernutrition is the leading cause of tuberculosis (TB) globally, but nutritional
49 interventions are often considered cost prohibitive. The RATIONS study demonstrated that nutritional
50 support provided to household contacts of persons with TB can reduce TB incidence. However, the long-
51 term cost-effectiveness of this intervention is unclear.

52 **Methods:** We assessed the cost-effectiveness of a RATIONS-style intervention (daily 750 kcal dietary
53 supplementation and multi-micronutrient tablet). Using a Markov state transition model we simulated
54 TB incidence, treatment, and TB-attributable mortality among household contacts receiving the
55 RATIONS intervention, as compared to no nutritional support. We calculated health outcomes (TB cases,
56 TB deaths, and disability-adjusted life years [DALYs]) over the lifetime of intervention recipients and
57 assessed costs from government and societal perspectives. We tested the robustness of results to
58 parameter changes via deterministic and probabilistic sensitivity analysis.

59 **Findings:** Over two years, household contacts receiving the RATIONS intervention would experience 39%
60 (95% uncertainty interval (UI): 23–52) fewer TB cases and 59% (95% UI: 44–69) fewer TB deaths. The
61 intervention was estimated to avert 13,775 (95% UI: 9036–20,199) TB DALYs over the lifetime of the
62 study cohort comprising 100,000 household contacts and was cost-effective from both government
63 (incremental cost-effectiveness ratio: \$229 per DALY averted [95% UI: 133–387]) and societal
64 perspectives (\$184 per DALY averted [95% UI: 83–344]). The results were most sensitive to the cost of
65 the nutritional supplement.

66 **Interpretation**

67 Prompt nutritional support for household contacts of persons with TB disease would be cost-effective in
68 reducing TB incidence and mortality in India.

69
70
71
72

73 **INTRODUCTION**

74 Tuberculosis (TB) has regained its position as the leading infectious cause of death worldwide, with 10.6
75 million cases and 1.3 million deaths in 2022.(1) Undernutrition blunts the innate and adaptive immune
76 response to *Mycobacterium tuberculosis*, the pathogen that causes TB.(2) At least 2.2 million of 10.6
77 million TB cases are attributable to undernutrition, making it the leading risk factor for TB.(1) There is
78 also evidence that, among individuals diagnosed with TB disease, undernourished individuals face higher
79 risks of death, treatment failure, and relapse despite undergoing antimycobacterial therapy.(2, 3)
80 Historical data suggest that nutritional supplementation could have a beneficial role by reducing the
81 incidence of TB disease and reducing case fatality among those with TB disease.(2) However, in the
82 absence of contemporary empirical data, nutritional supplementation for persons with TB (PWTB) and
83 their household contacts (HHCs) has not been widely adopted.

84
85 The recently published RATIONS study randomized more than 10,000 household contacts of persons
86 with TB in eastern India between a control arm that received routine TB care with no additional in-kind
87 nutritional supplementation and an intervention arm that received macronutrient and micronutrient
88 support with a food basket that cost \$13 per month for 6 months.(4) Compared to the control group,
89 the intervention group experienced a 40% reduction in TB incidence over the following two years. PWTB
90 in the RATIONS study, who also received nutritional support regardless of whether their household
91 contacts were in the control or intervention groups, experienced an approximately 35% reduction in
92 mortality compared to a previous National TB Elimination Program cohort. The RATIONS study shows
93 the potential nutritional supplementation to prevent TB incidence and mortality among household
94 contacts of PWTB.

95

96 In this study, we developed a Markov state transition model to explore if a RATIONS-style nutritional
97 intervention would be cost-effective for reducing TB incidence and mortality in India.

98 **METHODS**

99

100 **Study Design**

101 We used a Markov cohort model to estimate the long-term costs and health outcomes of providing a
102 food basket to HIV-negative household contacts of PWTB in India. We parameterized intervention costs
103 and effect sizes from the results of the RATIONS study, which was conducted among household contacts
104 of PWTB in Jharkhand, India, in a largely rural population with a high degree of multidimensional
105 poverty.(4) We conducted the study from the perspective of India’s central government, which funds
106 the National TB Elimination Program (NTEP). Recognizing that patient costs can often be substantially
107 larger than provider costs, we also conducted a secondary analysis to estimate results from a societal
108 perspective, considering costs borne by both patients and the Indian government. We programmed the
109 model using TreeAge Pro v.22.2.0 (Tree Age, Williamstown, MA).

110

111 **Intervention strategies**

112 We modeled two strategies. The “usual intervention” strategy reflects the status quo wherein
113 household contacts and PWTB do not receive any in-kind nutritional support. In the RATIONS
114 intervention, HHCs of PWTB receive a food basket that contains a daily multi-micronutrient tablet, rice,
115 and lentils for 6 months.(4) The food basket provides 23g of protein and a total of 750 Kcal calories daily.
116 In addition, under the RATIONS intervention we assumed that individuals progressing to TB disease
117 would receive a nutritional supplement that provided 1200 Kcal with 52g of protein for all six months of
118 TB treatment.

119

120 **Study Model**

121 The Markov model simulates the natural course of TB incidence, cure, and sequelae for a starting cohort
122 without TB disease. The model was constructed as a set of mutually exclusive health states, with natural
123 history transitions represented by movements between these health states: development of TB disease,
124 TB cure, death from TB, and death from other causes (Figure 1). Parameters defining TB incidence rates
125 were specified to represent differences in the rates of progression to TB disease based on individual
126 nutritional status. Individuals developing TB disease could die, self-cure, or be cured via treatment.
127 Individuals who survive TB transition to an early post-treatment state, where they have an elevated risk
128 of recurrent disease for 12 months as well as increased all-cause mortality. Following 12 months in the
129 early-post treatment phase, individuals transition to the late post-treatment phase, where they continue
130 to have increased all-cause mortality, but where their risk of TB disease falls to baseline. We assumed
131 that after surviving TB, individuals would have a lower average quality of life due to chronic post-TB lung
132 disease. We used the model to simulate progression of a cohort of 100,000 household contacts of PWTB
133 through these health states over their lifetime, with a 6-month time step.

134

135 **Parameter inputs**

136

137 *Health Outcomes*

138 Outcomes from the simulation included TB disease incidence, TB deaths, disability-adjusted life years
139 (DALYs), and costs from the government perspective. In a secondary analysis, we also considered costs
140 from a societal perspective. All outcomes were assessed over the lifetime of the modelled cohort.

141

142 We sourced TB incidence rates for HHCs after exposure from a previous meta-analysis.(5) Table 1

143 presents incidence estimates adopted for the analysis for the first five years. After five years of elevated

144 risk of TB disease, we assumed the incidence would drop to prevailing rates in the general Indian
145 population based on WHO estimates. (3) To account for the long-term secular declines in population TB
146 incidence rates, we assumed a 3% annual decline based on incidence trends estimated for India over the
147 past five years (Supplementary Figure 1). In the early post-treatment phase, we assumed that TB
148 survivors had an increased risk of recurrent TB based on observed data from India.(6) In the late post-
149 treatment phase, the risk dropped to baseline.

150
151 We obtained TB case fatality rates from the WHO Global TB Report 2022.(3) For background mortality
152 rates, we constructed TB-deleted life tables using WHO life tables.(7) For individuals surviving TB, we
153 estimated a lifetime increase in TB-attributable mortality using previous conservative estimates.(8)

154
155 To calculate DALYs, we obtained disability weights for TB disease from the Global Burden of Disease
156 Study 2019.(9) We estimated the disability weight for TB survivors (due to persistent sequelae) to be
157 0.053 based on a published study of the global burden of post-TB lung disease.(10)

158
159 *Intervention impact*

160 We assumed that prompt nutritional supplementation would reduce the risk of incident TB disease
161 among HHCs. Based on the results of the RATIONS study, we assumed an incidence rate ratio of 0.61
162 (95% CI 0.43, 0.85) for HHCs receiving supplementation compared to no supplementation for two years
163 from the beginning of the intervention. After two years, we assumed that those receiving the
164 intervention and those receiving usual care had a similar risk of incident TB disease. We assumed that
165 PWTB who receive nutritional support have reduced TB-related mortality based on a comparison of
166 outcomes of PWTB in the RATIONS study to an NTEP cohort, operationalized as a risk ratio of 0.65 (95%
167 CI: 0.49, 0.85) applied between TB incidence and cure.(6, 11)

168

169 We used cost data from the RATIONS study, which reported supplementation costs of \$13 per month
170 inclusive of delivery costs. In sensitivity analyses, we examined a wide range of values for the cost of the
171 nutritional supplementation, to account for regional variation, diversion of food grains, and wastage. We
172 obtained TB treatment costs from a recent published study.(12) For costs borne by TB patients and
173 affected households, we assumed that the direct medical costs, direct non-medical costs, and
174 productivity losses borne by TB-affected household would be \$700 (SD: 140) per TB episode.(13, 14) We
175 rounded all costs to the nearest dollar. All costs are reported in 2022 US dollars.

176

177 **Cost-effectiveness analysis**

178 We employed the model to compare the RATIONS nutritional supplementation intervention to the
179 status quo. We projected TB cases, TB deaths, disability-adjusted life-years (DALYs) attributable to TB,
180 and costs for each strategy over the lifetime of the study cohort. We calculated incremental cost-
181 effectiveness ratios (ICERs) as the ratio of mean incremental costs to mean incremental health benefits,
182 for the intervention compared to the usual care strategy. Costs and DALYs were discounted at 3% per
183 annum.(15)

184

185 *Willingness-to-pay*

186 We derived our willingness-to-pay (WTP) threshold from Ochalek et al., who estimated country-specific
187 willingness-to-pay thresholds based on the opportunity cost of healthcare spending.(16) For India, this
188 study estimated a WTP threshold equivalent to 23% of per-capita GDP (US\$550 in 2022). We considered
189 ICERs below this threshold to be clearly cost-effective.

190

191 **Sensitivity analysis**

192 To assess the robustness of our results, we conducted both deterministic and probabilistic sensitivity
193 analyses.(17) For the deterministic sensitivity analysis, we defined *a priori* feasible ranges around core
194 parameter values (Table 1) and then repeated the analysis multiple times, each time varying one
195 parameter between the maximum and minimum of the feasible range, with other parameters held at
196 their point estimate. Next, we conducted two-way sensitivity analyses, in which we simultaneously
197 varied the parameters that emerged as the most important from one-way sensitivity analyses.
198
199 Lastly, we performed probabilistic sensitivity analysis (PSA). We defined uncertainty in parameter values
200 as probability density functions (PDFs) for each model parameter. We then employed 2nd-order Monte
201 Carlo simulation to repeat the analysis 10,000 times, each time drawing a random value for each model
202 parameter from its PDF. This produced 10,000 estimates for each model outcomes, with the distribution
203 of these estimates quantifying the uncertainty in model outcomes due to the combined uncertainty
204 from all model parameters. We report the PSA results using cost-effectiveness acceptability curves.(18)
205 In addition, we report uncertainty around main analysis results using 95% uncertainty intervals
206 calculated from the PSA results.

207

208 **RESULTS**

209 **Base Case Results**

210 Base case results are presented in Table 2. Per 100,000 household contacts, those receiving the
211 RATIONS intervention had lower cumulative TB incidence over their lifetime compared to those
212 receiving usual care (6749 cases [95% uncertainty interval (UI): 5524–8520] vs. 7718 [95% UI: 6261–
213 9734]), risk ratio (RR) 0.87 [95% UI: 0.83–0.93]). In the first two years of this model, there were 1580 TB
214 cases (95% UI: 1074–2461) in the RATIONS intervention as opposed to 2577 TB cases (95% UI: 1898–

215 3634) with usual care, RR 0.61 (0.48–0.77). These results are consistent with the empirical findings of
216 the RATIONS trial.

217
218 The cohort receiving the RATIONS intervention was also estimated to have lower lifetime TB mortality
219 (906 [95% UI: 667–1288] vs. 1529 [95% UI: 1196–2044] TB deaths, RR 0.59 [95% UI: 0.49–0.72]). In the
220 first two years, there were 198 TB deaths (95% UI: 127–335) under the RATIONS intervention vs. 479
221 (95% UI: 343–710) under the usual care strategy (RR 0.41 [95% UI:0.31–0.56]). Per 100,000 individuals,
222 the RATIONS intervention averted 13,775 DALYs (95% UI: 9036–20,199) compared to usual care. The
223 majority of DALYs were averted in the RATIONS arm through reductions in TB mortality. Disaggregated
224 DALY estimates for each strategy are reported in Table 3.

225
226 Under the governmental perspective total (discounted) costs for the usual care strategy were \$0.76
227 million (95% UI: 0.52–1.11) per 100,000 individuals, representing the costs of treatment for individuals
228 developing TB. Total governmental costs under the RATIONS intervention were \$3.93 million (95% UI:
229 2.89–5.18), with \$0.66 million (95% UI: 0.45–0.96) of this total due to the costs of TB care, and the
230 remainder due to the costs of the nutritional intervention. Under the societal perspective total cost
231 were \$5.24 million (95% UI: 2.97–5.68) for the usual care strategy. Total societal costs under the
232 RATIONS intervention were \$7.76 million (95% UI: 5.71-10.58).

233
234 The incremental cost-effectiveness ratio of the RATIONS intervention, as compared to the status quo,
235 was \$229 per DALY averted (95% UI: 133–387) under the healthcare perspective and \$184 (95% UI: 83–
236 344) under the societal perspective. Both these estimates are below the country specific WTP threshold
237 of \$550 per DALY averted.

238

239 **Sensitivity analysis**

240 One-way sensitivity analyses for the general population showed that the two parameters with the
241 greatest impact on the ICER were the pre-recipient cost of the RATIONS supplementation (baseline
242 assumption: \$28.5, range: \$20-100) and the risk ratio of TB incidence for those receiving the nutritional
243 supplementation (baseline assumption: 0.61, range: 0.43 to 0.85) (Table 4). In threshold analyses, the
244 cost-effectiveness ratio for the RATIONS intervention was below to the WTP threshold (\$550 per DALY
245 averted) when the cost of supplementation was less than \$75, indicating that the intervention would be
246 cost-effective for any supplementation cost below this value. Even when we assumed the risk ratio for
247 TB incidence was 0.99, the WTP threshold was not exceeded. The model was less sensitive to the risk
248 reduction in TB mortality, the cost of TB treatment, and the disability weight for post-TB lung disease
249 (Table 4).

250 In two-way sensitivity analyses, the RATIONS intervention was cost-effective across a large range of
251 costs of the supplement and risk ratio of TB incidence (Figure 3). When the cost of the supplement for
252 HHCs was below \$56, the intervention was always cost-effective from the government perspective.
253 When considering the societal perspective, the intervention remained below the WTP threshold as long
254 as the supplementation cost was below \$59. We also conducted a two-way sensitivity analysis of the risk
255 ratios for TB incidence and TB mortality. Even at the lowest estimates of the risk ratio for TB incidence
256 (0.85) and TB mortality (0.85), the RATIONS intervention remained cost-effective with an ICER of \$514.

257
258 Lastly, in probabilistic sensitivity analysis, the RATIONS intervention was favored at a WTP of \$550 in
259 99.95% and 99.97% of model simulations from both the government and societal perspectives,
260 respectively. Indeed, RATIONS was consistently preferable in >99% of iterations at a WTP of \$440. From
261 a societal perspective RATIONS was consistently favorable in >99% of iterations at a WTP of \$396. Cost

262 effectiveness acceptability curves demonstrate the points at which RATIONS becomes consistently cost-
263 effective (Figure 3).

264

265 **DISCUSSION**

266 Nutritional interventions to mitigate risks of TB incidence and mortality are often perceived to be cost
267 prohibitive. However, the RATIONS study has provided empirical evidence that low-cost nutritional
268 support could have a substantial impact on lowering the risk of incident TB in settings with high rates of
269 multidimensional poverty and undernutrition. Our analysis suggests that an in-kind nutritional
270 intervention modelled on the food basket used in the RATIONS study could be cost-effective for
271 reducing TB incidence and mortality in India. We estimated that RATIONS-style nutritional support
272 would have a cost-effectiveness of \$229 per DALY averted from a healthcare perspective and \$184 per
273 DALY averted from a societal perspective. Our findings can help national TB programs as they consider
274 the economics of implementing nutritional support to reduce the incidence of TB among household
275 contacts.

276

277 Balanced nutritional interventions likely reduce incident TB disease by enhancing the humoral and
278 innate responses to *Mycobacterium tuberculosis*; these responses can help infected individuals
279 eliminate or contain the bacilli.(2) Nutritional support to malnourished individuals may acutely restore
280 their immune response. Indeed, mouse models suggest that providing a protein-rich diet to protein-
281 deficient mice can restore their anti-tubercular immune response within two weeks.(19) Given that the
282 majority of TB disease in high burden settings arises from infection within the past two years, nutritional
283 support should be provided to HHCs promptly after the diagnosis of the index case to prevent incident
284 TB disease.(20)

285

286 In our model, we limited the reduction in TB incidence among HHCs to two years after exposure since
287 this was the duration of follow-up observed in the RATIONS study. For subsequent years, we assumed
288 that individuals receiving the RATIONS intervention would have the same incidence rate as the usual
289 care group, which remained elevated in years 3, 4, and 5 since exposure. Given the impact of nutritional
290 support on the immune response to TB, it is possible that individuals receiving improved nutrition are
291 more resistant to new TB infection. If so, the incidence reductions produced by the RATIONS
292 intervention could extend beyond the two years assumed in this analysis. As such, our health impact and
293 cost-effectiveness estimates may be conservative.

294
295 It is important to note that that the RATIONS study—on which this cost-effectiveness analysis was
296 based—was conducted in a population with high levels of material deprivation and undernutrition, and
297 TB incidence rates higher than those estimated for other parts of India. It is possible that the impact and
298 cost-effectiveness of nutritional support may be lower in settings with a lower prevalence and severity
299 of undernutrition, or lower TB incidence. Our two-way sensitivity analysis suggests that even at the
300 lowest estimates of risk reduction for TB incidence (15% reduction) and mortality (15% reduction), the
301 intervention would remain below the WTP threshold. These are credible effect sizes in less
302 impoverished populations. A systematic review, which largely drew on data from high income countries,
303 found a log-linear relationship between BMI and TB incidence wherein TB incidence decreases by
304 approximately 14% per $1\text{kg}/\text{m}^2$ increase in BMI which is entirely achievable in 6 months on the RATIONS
305 intervention. Further, a systematic review of randomized trials of macronutrient supplementation in
306 PWTB, despite being underpowered, estimated that macronutrient supplementation was associated
307 with a RR of 0.34 (95% CI: 0.10–1.20) for TB mortality.(21)

308

309 Public health investments to eliminate TB and undernutrition have historically provided some of the
310 greatest returns on investment.(22, 23) The ICER estimated for nutritional support in our study is
311 considerably below both the country-specific WTP threshold for India and the ICER for well-accepted TB
312 preventive interventions, such as test-driven isoniazid preventive therapy for persons with HIV/AIDS
313 (\$1154 per DALY averted).(24) In our model, the ICER was most sensitive to the cost of nutritional
314 supplementation for HHCs. Even when we assumed the lowest possible effect of nutritional
315 interventions on incident TB disease, nutritional support would be cost-effective at \$56 per recipient
316 over 6 months, which was nearly twice the cost of the intervention. It is possible that state and national
317 governments would enjoy economies of scale, not possible in the context of a clinical trial, that
318 consequently could further lower the cost of the intervention.

319
320 Our analysis has several limitations. First, we did not model the impact of nutritional interventions on
321 reducing early relapses and disengagement from care, even though these are plausible effects.(2, 25)
322 Second, we did not account for reductions in TB transmission and secondary TB cases that might result
323 from lower TB incidence, and instead focused on the direct health benefits experienced by intervention
324 recipients. Third, our cost assumptions were limited to drug-susceptible TB, which is less costly to treat
325 than drug-resistant TB, (13) and we also did not model the medical and non-medical costs faced by
326 PWTB prior to their diagnosis. Approximately two-thirds of Indian PWTB treated in the public sector first
327 seek care in the private sector and accrue large costs before an accurate TB diagnosis is made.(13) Forth,
328 the model did not capture the positive externalities of nutritional support, including improvements in
329 nutritional status and functional recovery and improved economic productivity among TB survivors,
330 which have been explored in a previous analysis.(26) Taken together, these limitations suggest that our
331 ICER estimates will be conservative, and that nutritional support could be even more cost-effective than
332 we project.

333

334 Improvements in population-level nutrition and progress on social determinants of health likely
335 contributed to the massive decline in TB incidence and mortality in countries like the United States and
336 the United Kingdom that occurred even prior to the introduction of antimicrobials.(25) The striking
337 findings of the RATIONS study have demonstrated the role nutritional interventions can play in the
338 contemporary era to accelerate TB elimination. India is well positioned to institute a large-scale
339 nutritional support program as it already has well-established infrastructure for delivering in-kind
340 rations, mid-day meals, and nutritional counseling.(27-29) The TB Mitra Program, which crowdsources
341 nutritional support for persons with TB, could also be scaled up.(30)

342

343 Additional research is necessary to help us understand how to target nutritional interventions equitably
344 and efficiently. Operational studies are needed to design optimal delivery systems. Even as nutritional
345 interventions are operationalized in settings with lower prevalence of undernutrition in India,
346 epidemiological studies can help us understand the effect size of nutritional interventions in diverse
347 populations. We also need clinical and translational studies to better define the nutritional needs of
348 special populations, such as pregnant women and children, to develop the best possible nutritional
349 package. Economic evaluations should be conducted alongside nutritional intervention studies to inform
350 policy.

351

352 In conclusion, our analysis projected that a RATIONS-style intervention would be cost-effective for
353 populations with a high dual burden of TB and undernutrition in India and drive large reductions in TB
354 incidence and mortality among household contacts of persons with TB.

355

356

357 **FUNDING**

358 This work was supported by the National Institutes of Health [grant number K01AI167733-01A1 to PS] ;
359 the Burroughs Wellcome/ASTMH Postdoctoral fellowship to PS; US Civilian Research and Development
360 Foundation [grant number USB-31150-XX-13 to PS] with federal funds from the Government of India's
361 Department of Biotechnology, the Indian Council of Medical Research, the National Institutes of Health,
362 the National Institute of Allergy and Infectious Diseases, and the Office of AIDS Research and distributed
363 in part by CRDF Global [DAA3-19-65673-1]; grant from the Warren Alpert Foundation to PS); and a
364 career investment award by the Department of Medicine at Boston University Chobanian & Avedisian
365 School of Medicine. The funders had no role in study design, analysis, or reporting.

366

367 **CONFLICTS OF INTEREST**

368 We do not report any conflicts of interest.

369

370 **TABLES AND FIGURES**

371

372 **Table 1: Model assumptions**

Model Parameters	Point estimate (Ranges)	Distribution	Sources
Monthly cost of nutritional support for household contacts	\$4.75 (standard deviation: 0.95)	Gamma	Bhargava et al. (2023)(4)
Monthly cost of nutritional support for persons with TB			
Cost of nutritional support for persons with TB (6 months)	\$14.7 (standard deviation: 2.9)	Gamma	Bhargava et al. (2023)(11)
Cost of TB treatment (healthcare perspective)	\$102.77 (standard deviation: 15)	Gamma	Chatterjee et al. (2021)(12)
Cost of TB treatment (societal perspective)	\$700 (standard deviation: 70)	Gamma	Sinha et al. (2020) (13) Portnoy et al. (2023) (14)
Risk ratio incidence	0.61 (0.43-0.85)	PERT	Bhargava et al. (2023) (4)
Risk ratio mortality	0.65 (0.49-0.85)	PERT	Bhargava et al. (2023)(11) Velayutham et al. (2018)(6)
Start Age	40 years	-	
TB Incidence rate per 100,000	Year 1: 1478 (897-2427) Year 2: 831 (624-1106) Year 3: 1101 (757-1599) Year 4: 492 (344-704) Year 4: 549 (415-726) Beyond year 5: National TB incidence rates declining at 3% annually	-	Fox et al (2013).(5) Global TB report 2022(1)
Case fatality rate	17% (12%-24%)	PERT	WHO global TB report 2022(1)
Annual disability weight of TB disease	0.333 (0.224-0.454)	Beta	Global burden of disease 2019 (9)
Annual disability weight for post-TB disability	0.053 (0.026-0.079)	Beta	Quaife et al. (2020) (10)
Post-TB mortality risk ratio	1.14 (1.02-1.34)	PERT	Menzies et al. (2021) (8)
Risk of recurrent TB after treatment completion	0.13 (0.10-0.16)	Beta	Velayutham et al. (2018)

373

374

375

376

377

378

379

380

381

382

383

384 **Table 2: Outcomes per 100,000 individuals**

385 (DALYs: disability-adjusted life years; ICER: incremental cost effectiveness ratio [\$/DALYs averted]. Costs
386 and DALYs discounted)

387

Strategy	DALYs (95% CI)	Healthcare cost (95% CI)	Healthcare ICER (95% CI)	Societal cost (95% CI)	Societal ICER (95% ICER)
Usual care	41,172 (35,673-49,015)	\$0.76 million (0.52-1.11)	Ref	\$5.24 million (2.97-5.68)	Ref
RATIONS	27,397 (22,208-35,452)	\$ 3.93 million (2.89-5.18)	\$229 (133-387)	\$7.76 million (5.71-10.58)	\$184 (83-344)

388

389

390 **Table 3: Sources of DALYs per 100,000 in the two strategies**

391

Component of Disability-adjusted Life Years	Usual care	RATIONS
Years lost to TB mortality	29,705 (22,820-40,615)	16,951 (12,298-24,682)
Years lost to incremental post-TB mortality	6,209 (2087-13,596)	5,760 (1958-12,589)
Years lost to disability from TB disease	1,245 (877-1784)	1,071 (756-1538)
Years lost to disability from post-TB chronic lung disease	4,013 (2910-5544)	3,615 (2626-5027)
Total	41,172 (35,673-49,015)	27,397 (22,208-35,452)

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413
414

Table 4: Results of one-way sensitivity analyses from a healthcare perspective

Variable Description	Variable Low	Variable Base	Variable High	Impact on ICER	ICER Low	ICER High
Incremental cost of supplement for HHC (\$)	20	28.5	100	Increase	125	675
Risk ratio of TB incidence	0.43	0.61	0.85	Increase	132	288
Risk ratio of TB mortality	0.49	0.65	0.85	Increase	147	262
Case fatality rate in usual group	0.12	0.17	0.24	Decrease	142	237
Incremental cost of supplement for PWTB (\$)	40	88.2	200	Increase	161	236
Probability of TB recurrence	0.04	0.06726	0.12	Decrease	171	191
Cost of TB treatment (\$)	100	700	300	Decrease	214	229
Annual disability weight of post-TB lung disease	0.0265	0.053	0.0795	Decrease	181	186
Risk ratio of post-TB mortality	1.02	1.14	1.34	Decrease	183	184


415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438

439

440

441

442 **Figure 1: State transition diagram of model**



443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458


459

460

461

462

463 **Figure 3: Two-way sensitivity analysis of the cost of intervention and risk ratio of TB incidence** Areas
464 shaded blue denote that the intervention would be clearly cost-effective and red shaded regions
465 indicate that the willingness-to-pay threshold of \$550 was exceeded from the government perspective
466 and usual care is preferred.
467




468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492

493 **Figure 4: Cost-effectiveness acceptability curves**


494 Cost-effectiveness acceptability curves for the models with A. government perspective and B. societal
495 perspective. The blue line denotes the RATIONS intervention, and the red line indicates usual care. X-
496 axis denotes willingness-to-pay and the Y-axis denotes the percentage of iterations (out of 10,000
497 iterations) in which a particular strategy was favored for a particular willingness-to-pay threshold. Areas
498 shaded blue are below the willingness-to-pay threshold of \$550 and those shaded red are above that
499 threshold.

500 **A.**




501
502

B.



503

504
505 **Supplementary Figure 1:** TB incidence assumptions for the model. The first five years, the incidence is
506 elevated as reported in a previous systematic review.(5) Thereafter, we projected that the incidence
507 would drop to the TB incidence rate in India as defined in the WHO Global Tuberculosis Report 2022. We
508 assumed an annual 3% decrease in incidence due to secular reasons.
509



510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531

532 **References**

- 533
- 534 1. World Health Organization. Global tuberculosis report 2022. WHO, Geneva. 2022.
- 535 2. Sinha P, Davis J, Saag L, Wanke C, Salgame P, Mesick J, et al. Undernutrition and tuberculosis:
- 536 public health implications. *The Journal of infectious diseases*. 2019;219(9):1356-63.
- 537 3. Sinha P, Ponnuraja C, Gupte N, Babu SP, Cox SR, Sarkar S, et al. Impact of Undernutrition on
- 538 Tuberculosis Treatment Outcomes in India: A Multicenter Prospective Cohort Analysis. *Clin*
- 539 *Infect Dis*. 2022.
- 540 4. Bhargava A, Bhargava M, Meher A, Benedetti A, Velayutham B, Teja GS, et al. Nutritional
- 541 supplementation to prevent tuberculosis incidence in household contacts of patients with
- 542 pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised,
- 543 controlled trial. *The Lancet*. 2023.
- 544 5. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic
- 545 review and meta-analysis. *European Respiratory Journal*. 2013;41(1):140-56.
- 546 6. Velayutham B, Chadha VK, Singla N, Narang P, Gangadhar Rao V, Nair S, et al. Recurrence of
- 547 tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated
- 548 under the Revised National Tuberculosis Control Programme, India: A multi-centric prospective
- 549 study. *PLoS One*. 2018;13(7):e0200150.
- 550 7. World Health Organization. Life tables by country: India [Available from:
- 551 <https://apps.who.int/gho/data/view.main.60740?lang=en>.
- 552 8. Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, et al. Lifetime
- 553 burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis
- 554 sequelae. *The Lancet Global health*. 2021;9(12):e1679-e87.
- 555 9. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369
- 556 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the
- 557 Global Burden of Disease Study 2019. *The Lancet*. 2020;396(10258):1204-22.
- 558 10. Quaife M, Houben RM, Allwood B, Cohen T, Coussens AK, Harries AD, et al. Post-
- 559 tuberculosis mortality and morbidity: valuing the hidden epidemic. *The Lancet Respiratory*
- 560 *medicine*. 2020;8(4):332.
- 561 11. Bhargava A, Bhargava M, Meher A, Teja GS, Velayutham B, Watson B, et al. Nutritional
- 562 support for adult patients with microbiologically confirmed pulmonary tuberculosis: outcomes
- 563 in a programmatic cohort nested within the RATIONS trial in Jharkhand, India. *The Lancet*
- 564 *Global Health*. 2023;11(9):e1402-e11.
- 565 12. Chatterjee S, Toshniwal M, Bhide P, Sachdeva K, Rao R, Laurence Y, et al. Costs of TB
- 566 services in India (No 1). *The International Journal of Tuberculosis and Lung Disease*.
- 567 2021;25(12):1013-8.
- 568 13. Sinha P, Carwile M, Bhargava A, Cintron C, Acuna-Villaorduna C, Lakshminarayan S, et al.
- 569 How much do Indians pay for tuberculosis treatment? A cost analysis. *Public Health Action*.
- 570 2020;10(3):110-7.
- 571 14. Portnoy A, Yamanaka T, Nguhiu P, Nishikiori N, Baena IG, Floyd K, et al. Costs incurred by
- 572 people receiving tuberculosis treatment in low-income and middle-income countries: a meta-
- 573 regression analysis. *The Lancet Global Health*. 2023;11(10):e1640-e7.

- 574 15. Wilkinson T, Sculpher MJ, Claxton K, Revill P, Briggs A, Cairns JA, et al. The International
575 Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. *Value*
576 *Health*. 2016;19(8):921-8.
- 577 16. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and
578 middle-income countries: a novel approach and evidence from cross-country data. *BMJ global*
579 *health*. 2018;3(6):e000964.
- 580 17. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter
581 estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices
582 Task Force--6. *Value Health*. 2012;15(6):835-42.
- 583 18. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves--facts, fallacies and
584 frequently asked questions. *Health Econ*. 2004;13(5):405-15.
- 585 19. Chan J, Tian Y, Tanaka KE, Tsang MS, Yu K, Salgame P, et al. Effects of protein calorie
586 malnutrition on tuberculosis in mice. *Proceedings of the National Academy of Sciences*.
587 1996;93(25):14857-61.
- 588 20. Dowdy DW, Behr MA. Are we underestimating the annual risk of infection with
589 *Mycobacterium tuberculosis* in high-burden settings? *The Lancet Infectious Diseases*.
590 2022;22(9):e271-e8.
- 591 21. Grobler L, Nagpal S, Sudarsanam TD, Sinclair D. Nutritional supplements for people being
592 treated for active tuberculosis. *Cochrane Database of Systematic Reviews*. 2016;2016(6).
- 593 22. Estill J, Islam T, Houben RM, Rudman J, Ragonnet R, McBryde ES, et al. Tuberculosis in the
594 Western Pacific Region: Estimating the burden of disease and return on investment 2020–2030
595 in four countries. *The Lancet Regional Health–Western Pacific*. 2021;11.
- 596 23. Hoddinott J, Rosegrant M, Torero M. Hunger and malnutrition. *Copenhagen Consensus*;
597 2012.
- 598 24. Kapoor S, Gupta A, Shah M. Cost-effectiveness of isoniazid preventive therapy for HIV-
599 infected pregnant women in India. *The International Journal of Tuberculosis and Lung Disease*.
600 2016;20(1):85-92.
- 601 25. Carwile ME, Hochberg NS, Sinha P. Undernutrition is feeding the tuberculosis pandemic: a
602 perspective. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*. 2022:100311.
- 603 26. Sinha P, Lakshminarayanan SL, Cintron C, Narasimhan PB, Locks LM, Kulatilaka N, et al.
604 Nutritional Supplementation Would Be Cost-Effective for Reducing Tuberculosis Incidence and
605 Mortality in India: The Ration Optimization to Impede Tuberculosis (ROTI-TB) Model. *Clinical*
606 *infectious diseases : an official publication of the Infectious Diseases Society of America*.
607 2022;75(4):577-85.
- 608 27. Bhattacharya S, Falcao VL, Puri R. The Public Distribution System in India: Policy Evolution
609 and Program Delivery Trends. In: Bhattacharya S, Falcao VL, Puri R, editors. *The 15 Billion*
610 *People Question: Food, Vouchers, or Cash Transfers?: The World Bank*; 2017. p. 43-105.
- 611 28. Navaneethan P, Kalaivani T, Rajasekaran C, Sunil N. Nutritional status of children in rural
612 India: a case study from Tamil Nadu, first in the world to initiate the Mid-Day Meal scheme.
613 *Health*. 2011;3(10):647.
- 614 29. Scott K, Glandon D, Adhikari B, Ummer O, Javadi D, Gergen J. India's auxiliary nurse-
615 midwife, anganwadi Worker, and accredited social health activist programs. *Health for the*
616 *People: National Community Health Programs from Afghanistan to Zimbabwe* Edited by Perry H
617 Washington, DC, USA: USAID/Maternal and Child Survival Program. 2020:113-33.

618 30. National Tuberculosis Elimination P. Ni-kshay Mitra. Ministry of Health & Family Welfare.
619